3 results about "CREB" patented technology

The invention belongs to the technical field of gene detection, and particularly relates to a brand new application of a DDX42 gene or an expression product thereof as an acute myelogenous leukemia (AML) diagnosis and prognosis biomarker. Specific high expression of DDX42 in bone marrow and peripheral blood samples of AML patients is revealed for the first time, the expression level of DDX42 is remarkably different from that of a healthy control group, and DDX42 can be detected through real-time fluorescent quantitative PCR, western blot and other methods and is used for diagnosis, differential diagnosis, disease state evaluation or risk stratification of AML. Meanwhile, the invention clarifies a molecular mechanism that DDX42 promotes AML cell proliferation and inhibits apoptosis and differentiation through PLK1 and LIMK1-CREB-DNMT1 signal axes, and verifies that a transcription factor ERG is an upstream forward regulatory factor for the first time. Based on the discovery, the invention not only provides a novel high-sensitivity molecular diagnosis marker for AML, but also lays a solid experimental foundation for developing a novel AML treatment strategy and a drug screening system targeting DDX42 and related signal channels thereof. The method has the advantages of mature detection method, high marker relevance, clear application prospect and the like.

The invention discloses application of pinoresinol in treatment of rectal cancer, it is found for the first time that the pinoresinol can inhibit expression of CaLM1, then CaLM1 / CaMKII / CREB signaling pathways can be inhibited by reducing expression levels of CAMKII and p-CREB, and on the basis of the inhibition of the expression levels of CAMKII and p-CREB, the application of the pinoresinol in treatment of rectal cancer is achieved. The pinoresinol is used as an inhibitor of a CaLM1 / CaMKII / CREB signal channel for the first time, in-vitro and in-vivo effects on rectal cancer cells and solid tumors thereof are experimented, and it is found that in-vitro pinoresinol dose dependence reduces expression of CaLM1, CaMKII and p-CREB, proliferation of cancer cells is remarkably inhibited, apoptosis of the cancer cells is promoted, and the tumor cell cycle is retarded in the G0 / G1 phase. In-vivo experiments show that the volume and weight of tumors are reduced by dosages of the pinoresinol, and the experiments find that the rectal cancer inhibition effect of the high-concentration pinoresinol (20.0 mg / kg) is close to that of a known chemotherapeutic drug cis-platinum (8.0 mg / kg) with a curative effect; in addition, the TUNEL experiment and the immunohistochemical analysis further support the apoptosis promoting and anti-proliferation effects of the pinoresinol by inhibiting the CaLM1 / CaMKII / CREB signal channel.

The present application relates to the field of biological medicine, and provides an anti-phosphorylated CREB (Ser133) antibody and application thereof.The antibody J20C provided by the present application is selected from at least one of the following: (a) having light chain CDR sequences shown in SEQ ID NO: 3, 4 and 5, and having heavy chain CDR sequences shown in SEQ ID NO: 6, 7 and 8; (b) the light chain variable region has an amino acid sequence shown in SEQ ID NO: 1, and the heavy chain variable region has an amino acid sequence shown in SEQ ID NO: 2.In addition, the present application also discloses a single-chain antibody reformed by using the antibody, which has higher sensitivity and specificity.The single-chain antibody can be used as an auxiliary diagnostic tool for the occurrence and progression of Alzheimer's disease and epilepsy.